Literature DB >> 24309906

GM2 gangliosidosis in British Jacob sheep.

M E Wessels1, J P Holmes2, M Jeffrey3, M Jackson4, A Mackintosh5, E H Kolodny6, B J Zeng6, C B Wang6, S F E Scholes3.   

Abstract

GM2 gangliosidosis (Tay-Sachs disease) was diagnosed in 6- to 8-month-old pedigree Jacob lambs from two unrelated flocks presenting clinically with progressive neurological dysfunction of 10 day's to 8 week's duration. Clinical signs included hindlimb ataxia and weakness, recumbency and proprioceptive defects. Histopathological examination of the nervous system identified extensive neuronal cytoplasmic accumulation of material that stained with periodic acid--Schiff and Luxol fast blue. Electron microscopy identified membranous cytoplasmic bodies within the nervous system. Serum biochemistry detected a marked decrease in hexosaminidase A activity in the one lamb tested, when compared with the concentration in age matched controls and genetic analysis identified a mutation in the sheep hexa allele G444R consistent with Tay-Sachs disease in Jacob sheep in North America. The identification of Tay-Sachs disease in British Jacob sheep supports previous evidence that the mutation in North American Jacob sheep originated from imported UK stock. Crown
Copyright © 2013. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  G(M2) gangliosidosis; Jacob sheep; Tay–Sachs disease

Mesh:

Substances:

Year:  2013        PMID: 24309906     DOI: 10.1016/j.jcpa.2013.10.003

Source DB:  PubMed          Journal:  J Comp Pathol        ISSN: 0021-9975            Impact factor:   1.311


  3 in total

1.  Occipital condylar dysplasia in a Jacob lamb (Ovis aries).

Authors:  Alison M Lee; Nicola F Fletcher; Conor Rowan; And Hanne Jahns
Journal:  Open Vet J       Date:  2017-05-20

Review 2.  The Translational Benefits of Sheep as Large Animal Models of Human Neurological Disorders.

Authors:  Samantha J Murray; Nadia L Mitchell
Journal:  Front Vet Sci       Date:  2022-02-15

3.  Therapeutic advantages of combined gene/cell therapy strategies in a murine model of GM2 gangliosidosis.

Authors:  Davide Sala; Francesca Ornaghi; Francesco Morena; Chiara Argentati; Manuela Valsecchi; Valeria Alberizzi; Roberta Di Guardo; Alessandra Bolino; Massimo Aureli; Sabata Martino; Angela Gritti
Journal:  Mol Ther Methods Clin Dev       Date:  2022-03-16       Impact factor: 6.698

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.